A clinical study of adenovirus mediated Reduced Expression in Immortalized Cells/Dickkopf-3 (REIC/Dkk-3) gene therapy for malignant pleural mesothelioma.
Phase of Trial: Phase I/II
Latest Information Update: 03 Oct 2016
At a glance
- Drugs Ad SGE DKK3 gene therapy-Kyorin (Primary)
- Indications Pleural disorders
- Focus Adverse reactions
- 29 Sep 2016 Status changed from recruiting to discontinued.
- 18 Apr 2015 Status changed from suspended to recruiting as reported by University Hospital Medical Information Network.
- 17 Nov 2014 Status changed from recruiting to suspended as reported by University Hospital Medical Information Network.